KRAS Activating Mutation clinical trials at University of California Health
1 in progress, 0 open to eligible people
Showing trials for
Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
Sorry, in progress, not accepting new patients
This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.
at UCSF